As of November 9, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of KALA BIO, Inc. The largest reported stake is Oxford Finance LLC's, at 16.5%. 16 filings are on record since September 11, 2025 (Schedule 13G, December 3, 2025).
Sell to companies like KALA BIO, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Labkowski Nachum · Sole voting: 966,991 · Shared voting: 0 · Sole dispositive: 966,991 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-19
- · Reporting person: Lazar David E. · Sole voting: 719,404 · Shared voting: 0 · Sole dispositive: 719,404 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-02
- · Holder: Baker Bros. Advisors LP · Percent: 0.01% · SCHEDULE 13G/A
- · Holder: Baker Bros. Advisors LP · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: David E. Lazar · Percent: 5.18% · SCHEDULE 13D
KALA BIO, Inc. has 16 Schedule 13D or 13G filings on record since 2025-09-11. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 19 jobs, latest 2025-10-20 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Oxford Finance LLC | 16.5% | 1,620,000 | SCHEDULE 13G, 2025-12-03 | 2025-11-25 |
| LifeSci Capital LLC | 7.9% | 2,200,000 | SCHEDULE 13G, 2026-01-13 | 2025-12-30 |
| 5% | 966,991 | SCHEDULE 13G, 2026-10-19 | 2026-10-14 | |
| SR One Capital Management, LLC | 4.6% | 344,176 | SCHEDULE 13D/A, 2025-10-15 | 2025-10-14 |
| 3.9% | 719,404 | SCHEDULE 13D/A, 2026-07-02 | 2026-05-20 | |
| Baker Bros. Advisors LP | 0.01% | 2,312 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Point72 Asset Management, L.P. | 0% | 257 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Perceptive Advisors LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Cormorant Asset Management, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind KALA BIO, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on KALA BIO, Inc. and the records around it.
KALA BIO, Inc. elsewhere on the record
- Company profile and every filing Mar 2026
- Form D filing Mar 2026
- Form D filing Feb 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- SR One Capital Fund II Aggregator, LP also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- David E. Lazar also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Watch KALA BIO, Inc.
Get an email when KALA BIO, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on KALA BIO, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on KALA BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on KALA BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Labkowski Nachum | 966,991 | 0 | 966,991 | 0 | SCHEDULE 13G, 2026-10-19 |
| Lazar David E. | 719,404 | 0 | 719,404 | 0 | SCHEDULE 13D/A, 2026-07-02 |
The latest filing identifies KALA BIO, Inc. by CUSIP 483119301 and gives its principal executive office as 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA 02476 (SCHEDULE 13G, 2026-10-19).
Source of funds (Item 3)
Item 3 is hereby amended to add the following: The aggregate purchase price of the 719,404 Shares beneficially owned by the Reporting Person, which consists of Conversion Shares received by the Reporting Person upon the conversion of the Series AA Preferred Stock purchased by the Reporting Person pursuant to the SPA, is $1,308,007.Lazar David E., SCHEDULE 13D/A, 2026-07-02
Purpose of Transaction (Item 4)
SR One Capital Management, LLC
On October 7, 2025, Aggregator converted an aggregate of 4,110 shares of Series H Preferred Stock of the Issuer into 411,000 shares of the Issuer's Common Stock (the "Conversion"). Following the Conversion, on October 14, 2025, Aggregator sold 66,824 shares of the Issuer's Common Stock in a series of open market transactions. Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Stock that were effected by the Reporting Persons since the filing of Amendment No. 1. Depending on market conditions and other factors, Aggregator and the other Reporting Persons may dispose of additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-11 | Point72 Asset Management, L.P. | 6.7% | SCHEDULE 13G |
| 2025-09-11 | Perceptive Advisors LLC | 7.7% | SCHEDULE 13G |
| 2025-10-01 | SR One Capital Management, LLC | 5.5% | SCHEDULE 13D/A |
| 2025-10-02 | Baker Bros. Advisors LP | 9.99% | SCHEDULE 13D/A |
| 2025-10-03 | Baker Bros. Advisors LP | 9.99% | SCHEDULE 13G |
| 2025-10-15 | SR One Capital Management, LLC | 4.6% | SCHEDULE 13D/A |
| 2025-11-14 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Cormorant Asset Management, LP | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Perceptive Advisors LLC | 0% | SCHEDULE 13G/A |
| 2025-12-03 | Oxford Finance LLC | 16.5% | SCHEDULE 13G |
| 2026-01-13 | LifeSci Capital LLC | 7.9% | SCHEDULE 13G |
| 2026-02-06 | David E. Lazar | 5.18% | SCHEDULE 13D |
| 2026-02-17 | Baker Bros. Advisors LP | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Baker Bros. Advisors LP | 0.01% | SCHEDULE 13G/A |
| 2026-07-02 | Lazar David E. | 3.9% | SCHEDULE 13D/A |
| 2026-10-19 | Labkowski Nachum | 5% | SCHEDULE 13G |
Questions about who owns KALA BIO, Inc.
Who owns KALA BIO, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of KALA BIO, Inc.: Oxford Finance LLC (16.5%, Schedule 13G, filed 2025-12-03), LifeSci Capital LLC (7.9%, Schedule 13G, filed 2026-01-13) and Labkowski Nachum (5%, Schedule 13G, filed 2026-10-19).
Who are the largest shareholders of KALA BIO, Inc.?
By the share each holder's latest filing reports, the largest holders of KALA BIO, Inc. on this page are Oxford Finance LLC (16.5%), LifeSci Capital LLC (7.9%) and Labkowski Nachum (5%).
When did Oxford Finance LLC buy into KALA BIO, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Oxford Finance LLC on this page is the Schedule 13G, filed 2025-12-03, reporting 16.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for KALA BIO, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 17, 2026 | Form D, private offering | $1.75M sold | Form D page | Source |
| February 13, 2026 | Form D, private offering | $2.25M sold | Form D page | Source |
| December 31, 2024 | Form D, private offering | $10.75M sold | Form D page | Source |
KALA BIO, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for KALA BIO, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.